<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
	<title>BioToday.com [新着ニュース]</title>
	<description>BioToday.comは医学情報、バイオテクノロジー、バイオベンチャー関連ニュースのデータベースです。</description>
	<link>http://www.biotoday.com/news.cfm</link>
	<managingEditor>biotoday@biotoday.com</managingEditor>
	<copyright>Copyright &#169; 2026 BioToday Ltd. All Rights Reserved.</copyright>
	<lastBuildDate>Sun, 05 Apr 2026 17:00:32 +0900</lastBuildDate>
	<language>ja</language>
	<docs>http://blogs.law.harvard.edu/tech/rss</docs>
	<item>
		<title>[医学] 抗凝固薬が向く心房細動患者の左心耳閉鎖がNOAC抗凝固薬に劣らず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109593&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109593&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 05 Apr 2026 17:00:32 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109593&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 動脈硬化疾患患者のLDLコレステロールをより下げるのが有益〜韓国無作為化試験</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109592&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109592&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 05 Apr 2026 14:45:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109592&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 経皮エストラジオールがLHRHに比肩する前立腺癌治療を無作為化試験で達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109591&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109591&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 05 Apr 2026 14:08:07 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109591&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 先立つ治療を経ている進行固形癌患者3-4人に1人にG12D変異KRAS分解薬が有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109590&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109590&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験 || ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 05 Apr 2026 13:20:54 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109590&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ブタ精液の小胞を利用した点眼薬でマウスの網膜芽細胞腫の増殖を阻止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109589&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109589&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 05 Apr 2026 12:19:48 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109589&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Denali社との前頭側頭型認知症薬DNL593の提携を武田薬品が打ち切り</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109588&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109588&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 05 Apr 2026 10:20:38 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109588&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 1年近く前に米国FDAが差し止めたHIV薬Ph2/3試験の1つをGilead社が打ち切り</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109587&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109587&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 中止 || 開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 05 Apr 2026 09:44:03 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109587&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AstraZenecaの手持ち2品ImfinziとImjudo込み初期肝癌治療の無増悪生存改善達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109586&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109586&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 05 Apr 2026 08:40:38 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109586&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Immunovant社で二の次扱いのFcRn阻害薬が発奮せず甲状腺眼症Ph3試験失敗</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109585&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109585&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 04 Apr 2026 16:52:09 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109585&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 統合失調症絡みの認知障害へのAlto社のPDE4阻害薬ALTO-101のPh2試験失敗</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109584&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109584&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 04 Apr 2026 16:28:05 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109584&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] PfizerとBioNTechの新装COVID-19ワクチンの米国大規模試験が不人気で停止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109583&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109583&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / その他臨床試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 04 Apr 2026 15:55:29 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109583&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 脳の線条体の神経で発現するPDE10Aの阻害薬をAxsome社が武田薬品から取得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109582&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109582&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 04 Apr 2026 15:19:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109582&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] ORIC社のPh1b試験段階の前立腺癌薬のPh3試験用量が決まる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109581&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109581&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 04 Apr 2026 14:56:55 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109581&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 血液癌を治療するOrca Bio社の細胞詰め合わせOrca-Tの米国承認審査3か月延長</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109580&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109580&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認申請</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 04 Apr 2026 12:29:48 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109580&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Enveda社のJak阻害様経口薬ENV-294でアトピー性皮膚炎患者のEASIが68%低下</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109579&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109579&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 04 Apr 2026 11:53:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109579&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] EPP/XLP患者の耐日光時間が田辺のdersimelagonでプラセボ差し引き30分延長</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109578&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109578&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 04 Apr 2026 10:58:39 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109578&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Insilico Medicine社との新規提携でLillyが前臨床段階の経口治療の権利を取得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109577&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109577&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 04 Apr 2026 10:17:34 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109577&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Amgenの補体5a受容体阻害薬Tavneosの深刻な肝障害の注意を米国FDAが発した</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109576&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109576&amp;ref=rss</guid>
		<category>ビジネス / トラブル / 安全性</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 03 Apr 2026 16:57:45 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109576&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] BiogenがApellis社を56億ドルほどで買って承認済みの補体阻害薬を手にする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109575&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109575&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 03 Apr 2026 16:07:57 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109575&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Infinimmune社の技術頼みの抗体薬開発にMerck &amp; Coが取り組む</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109574&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109574&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 03 Apr 2026 15:11:47 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109574&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Lillyがまず63億ドルを払って目覚ましOX2R活性化薬のCentessa社を買う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109573&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109573&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 03 Apr 2026 12:34:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109573&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 低ホスファターゼ血症の小児患者に限りAstraZenecaのALP酵素活性補充薬が有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109572&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109572&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 03 Apr 2026 10:23:51 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109572&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 生命科学の企業/製品への投資資金63億ドルをBlackstoneが集金</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109571&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109571&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 03 Apr 2026 08:41:32 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109571&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Lillyの経口GLP-1薬Foundayoも米国FDAが承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109570&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109570&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 03 Apr 2026 07:05:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109570&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 自己免疫性肝炎薬zetomipzomibを持て余すKezar社をAurinia社が買う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109569&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109569&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Apr 2026 07:18:56 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109569&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] スタチン継続高脂血症患者のLDL-CがMerck &amp; Coの経口PCSK9阻害薬で65%低下</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109568&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109568&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Apr 2026 06:13:49 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109568&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Viridian社の皮下注射の抗IGF-1R抗体elegrobart甲状腺眼症Ph3試験目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109567&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109567&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Apr 2026 05:40:19 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109567&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 皮膚エリテマトーデスへのBiogenの抗BDCA2抗体litifilimabのPh2試験2つ目も成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109566&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109566&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 31 Mar 2026 16:19:39 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109566&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] MoonLakeとIncyte社の化膿性汗腺炎Ph3試験の長期結果報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109565&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109565&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 31 Mar 2026 15:30:57 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109565&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 心不全と肺高血圧の併発症へのMerck &amp; CoのWinrevairのPh2試験が成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109564&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109564&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 31 Mar 2026 14:37:04 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109564&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] PriovantのTYK2/JAK1阻害薬brepocitinibが皮膚筋炎に効いたPh3試験論文報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109563&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109563&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 31 Mar 2026 13:05:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109563&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] United社のトレプロスチニル吸入品Tyvasoの特発性肺線維症Ph3試験2つ目も成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109562&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109562&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 31 Mar 2026 12:15:09 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109562&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 1型糖尿病患者に移植した膵島（β細胞）がどれだけ持つかがNKX6.1発現量と関連</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109561&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109561&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 31 Mar 2026 10:39:23 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109561&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 赤血球運搬mRNAでキメラ抗原受容体(CAR)骨髄系細胞を体内で作る手段を開発</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109560&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109560&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 31 Mar 2026 10:27:10 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109560&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 心臓の酸素消費を測定する新たなMRI技術が心不全の早期検出に役立ちそう</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109559&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109559&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 31 Mar 2026 10:06:56 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109559&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Seaport社の抗うつ経口アロプレグナノロンGlyphAlloのPh1/2a試験結果報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109558&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109558&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 31 Mar 2026 09:50:04 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109558&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Nav1.7限定抑制ジンクフィンガー蛋白質が神経痛マウスに有効〜Ph1/2試験進行中</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109557&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109557&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 31 Mar 2026 08:20:55 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109557&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 先天性赤血球異形成貧血2型(CDAII)にリジン脱メチル化酵素LSD1阻害が効きそう</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109556&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109556&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 31 Mar 2026 07:31:53 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109556&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 【増補版】ペニスの思いもよらない一画が男性のGスポットらしい</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109555&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109555&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 31 Mar 2026 06:52:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109555&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 癌で生じる抗体が脳の自己免疫疾患の原因に変貌しうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109554&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109554&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 30 Mar 2026 13:44:24 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109554&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ペニスの思いもよらない一画が男性のGスポットかもしれない</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109553&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109553&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 29 Mar 2026 16:40:41 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109553&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] NovartisのB因子阻害薬FabhaltaがIgA腎症患者の腎不全への進展率を43%引き下げ</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109552&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109552&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 29 Mar 2026 15:33:25 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109552&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Ph3試験段階のPTSD薬を擁するTranscend Therapeutics社を大塚製薬が買う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109551&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109551&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 29 Mar 2026 14:20:02 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109551&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 体内で作るAstraZenecaのCAR-Tが進行多発性骨髄腫患者5人中4人に奏効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109550&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109550&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 29 Mar 2026 12:47:29 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109550&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AstraZenecaのIL-33結合薬tozorakimabの慢性閉塞性肺疾患Ph3試験2つが成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109549&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109549&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 29 Mar 2026 08:49:13 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109549&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Ph1試験段階アレルギー薬を擁するExcellergyをNovartisが最大20億ドルで買う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109548&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109548&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 28 Mar 2026 16:12:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109548&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 2型糖尿病成人へのNovo社の週1回皮下注射インスリン Awiqliを米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109547&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109547&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 28 Mar 2026 13:38:46 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109547&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Rocket社の白血球接着不全症1型（LAD-I）遺伝子治療Kresladiを米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109546&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109546&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 28 Mar 2026 11:56:48 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109546&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Innate Pharma社のNK細胞差し向け薬IPH6501のリンパ腫P1/2試験打ち切り</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109545&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109545&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験 || 開発 / 臨床試験 / 中止</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 28 Mar 2026 09:58:06 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109545&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Wave社のインヒビンβE標的薬WVE-007高用量の体重低下が低用量に見劣りする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109544&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109544&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 27 Mar 2026 16:41:08 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109544&amp;ref=rss</comments>
	</item>
</channel>
</rss>
